Open AccessEucalyptus globulus Methanol Leaf Extract Improves Glycosylated Hemoglobin, Lipid Profile Levels and Haematological Sub-inflammatory Biomarkers in Streptozotocin-induced Diabetic Rats
Author(s) -
Bamidele Stephen Ajilore,
Fatoki J.O,
Taiwo Adekemi Abayomi
Publication year - 2021
Language(s) - English
DOI - 10.53994/njbams.202111.4
Subject(s) - metformin , streptozotocin , medicine , lipid profile , eucalyptus globulus , malondialdehyde , diabetes mellitus , insulin , endocrinology , oxidative stress , eucalyptus , biology , botany
Background: Eucalyptus leaf is used traditionally to treat a lot of diseases, but little is known about its use in the management of diabetes mellitus (DM) and its complications. Objectives: Antidiabetic property of Eucalyptus globulus leaf extract (EGLEX) was assessed on recent Makers of therapeutic response and diabetic disease progression in streptozotocin-induced diabetic rats. Methods: Eucalyptus globullus leaf powder (200 g) was extracted with methanol using standard procedure. Hyperglycemia was induced in Wistar rats with single intravenous dose of 50 mg/kg/bwt streptozotocin. The rats were divided into five groups (n = 5): Anormal control, B- diabetic control, C, D and E were diabetic rats treated with Eucalyptus globullus leaf extract (EGLEX), metformin and insulin respectively for four weeks. Samples were collected for biochemical and hematological studies. Data obtained were analysed using One Way Analysis of Variance at <0.05 significance level. Results and Conclusion: The results showed significant (p<0.05) blood glucose reduction of 68%, 51% and 68%, and weight gain of 17%, 18% and 11% in rats treated with EGLEX, metformin and insulin respectively. HBA1c level was significantly (p<0.05) raised (9.30%) in diabeticuntreated rats when compared with normal control (3.77%), EGLEX (4.24%), metformin (4.94%) and insulin (5.33%) groups. The deranged lipid profile indices, malondialdehyde and reduced glutathione levels, superoxide dismutase activity, platelet count, % neutrophil and % lymphocyte were normalized in diabetic rats treated with EGLEX when compared with the values in diabetic untreated rats. The findings concluded that EGLEX possesses antidiabetic property and improves biomarkers of diabetic disease progression.